Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5652W HIGH $3.88
Volume
30.56 K
Value Traded
34.33 K
Short % Float
2.57%
Days to Cover
1.1
-19.67%Week
-51.65%1 Month
-56.65%3 Month
-63.24%6 Month
-95.18%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.64 M
EPS (TTM)
-1.96
P/E Ratio
-
Ent. Value
14.22 M
Total Shares
7.38 M
Float Shares
1.83 M
Insiders
75.20%
Institutions
2.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AIMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Ainos, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ainos, Inc.
106Total events
0Upcoming
26Tier-1 (high impact)
2020 to 2026Coverage
Event history 50
◆Full ResultsVeldonaClinical Data
Final analysis of VELDONA FCGS trial expected
feline chronic gingivostomatitis (FCGS)source ↗
▲Partnership / LicenseCorporate
Distribution partnership for front-end semiconductor opportunities
◆Enrollment MilestoneTrial
~1,400 systems under three-year $2.1 million deployment targeted for completion
semiconductor packaging and testingsource ↗
●Quarterly UpdateCorporate
Ainos reports full year 2025 financial results and commercial momentum
◆Enrollment MilestoneTrial
~200 AI Nose systems targeted for deployment in front-end wafer fabrication facilities for technical validation
semiconductor environmentsource ↗
▼Equity OfferingCorporate
New Taiwan Dollar 90 million financing (approx. USD$2,820,000) completed
◆Partnership / LicenseCorporate
Pursue additional strategic partnerships in Asia and Europe for technology licensing and regional commercialization
◆Enrollment MilestoneTrial
Initiate Phase 1 expansion to approximately 5,000 AI Nose units with ASEH
▲Patent GrantedIP / Competition
Seven new patents secured in Europe, Germany, Taiwan, and China
▲Product LaunchPost-Market
Launch of first commercial portable cloud-connected AI Nose module
▲Partnership / LicenseCorporate
Secured $2.1 million three-year subscription order with ASEH for AI Nose deployment in semiconductor manufacturing
▲Partnership / LicenseCorporate
Secured three-year $2.1M subscription order with ASEH for AI Nose in semiconductor manufacturing
▲Partnership / LicenseCorporate
ugo to pilot AI Nose-equipped service robots at seven sites in Japan
▲Partnership / LicenseCorporate
Expanded industrial footprint through partnerships with Kenmec and Solomon
▲Platform Validationsmell language modelPreclinical
Smell language model (SLM) surpassed 90% accuracy in classifying everyday scents
▲Platform ValidationPreclinical
Senior care program improved accuracy to ~85% from ~80%
senior caresource ↗
▲Partnership / LicenseCorporate
Five-year distribution partnership with Solomon for AI Nose in Asia manufacturing
▲Partnership / LicenseCorporate
Expanded strategic relationship with ASEH for multi-phase AI Nose deployment
▲Partnership / LicenseCorporate
Strategic partnership with Kenmec to deploy AI Nose and SLM in smart factories
▲Partnership / LicenseCorporate
Strategic partnership with Kenmec for AI Nose in smart factory ecosystem
▲Biomarker DataClinical Data
AI Nose accuracy improved to 85% in detecting excretion odors
hygiene monitoring in long-term caresource ↗
▲Interim AnalysisVeldonaTrial
Promising interim results from VELDONA FCGS trial: 10-44% symptom improvement, steroid-sparing effect
feline chronic gingivostomatitis (FCGS)source ↗
◆Timing GuidancePresentation
Next phase of AI Nose-ugo robot development: UI design and backend integration expected to complete within 2-4 weeks
▲Partnership / LicenseCorporate
Strategic partnership with ASE Chung Li to deploy AI Nose in semiconductor manufacturing
▲Partnership / LicenseCorporate
Installation of AI Nose on ugo robot; entering next phase of development
▲IND ClearanceVeldonaIND
IRB clearance from Taipei Medical University for VELDONA trial in primary Sjögren's syndrome
primary Sjögren's syndromesource ↗
◆IND SubmissionVeldonaIND
IND submission to FDA for HIV oral warts expected by H2 2025
HIV oral wartssource ↗
▲Partnership / LicenseCorporate
Strategic partnership with Advanced Semiconductor Engineering, Inc. for AI Nose in semiconductor manufacturing
▲Partnership / LicenseCorporate
Strategic partnership with ugo, Inc. to integrate AI Nose into robots
▲Patent GrantedVeldonaIP / Competition
Key invention patent granted in Japan for VELDONA oral interferon formulation for coronavirus
coronavirus infectionssource ↗
◆Timing GuidancePresentation
Pilot deployments at seven sites in Japan with robotics partner ugo, Inc.
◆Trial CompletionVeldonaTrial
FCGS trial report finalized
feline chronic gingivostomatitis (FCGS)source ↗
▲Trial InitiationVeldonaTrial
Began human clinical trial for primary Sjögren's syndrome in Taiwan
primary Sjögren's syndromesource ↗
▲Partnership / LicenseVeldonaCorporate
Signed MOU with Taiwan Tanabe Seiyaku for manufacturing and Taiwan market promotion
Sjögren's syndromesource ↗
Past FDA Catalysts and PDUFA Decisions
How AIMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
6
Drugs Scored
rNPV / MCap
Top Drug
Top 99%
Micro Cap(rank 650 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every AIMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| chiang yao-chungDirector | Buy | 3,500 11,279 held | $2.05 | 06/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AIMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in AIMD for Q2 2026. | ||||
AIMD Institutional Ownership Trends
AIMD Short Interest
Shares sold short, counted twice a month.
2.57%
Short % of Float
of tradable shares sold short
47.1K
Shares Sold Short
+14.2% vs prior count
1.1 Low
Days to Cover
trading days of normal volume to buy every short share back
42.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AIMD ranks across every disease it competes in
Competitive Position is a premium feature
See how AIMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAIMD News
AIMDAinos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets
Ainos, Inc. (NASDAQ:AIMD) reported its financial results for the first quarter of 2026, highlighting advancements in its AI Nose technology for semiconductor and healthcare infrastructure applications. The company has shifted focus from validation to more extensive deployments, showing strong operational milestones. A financing arrangement has enhanced their balance sheet, while a notable reduction in operating expenses showcases improved efficiency. The company is optimistic about future commercialization and revenue opportunities as it continues to expand its Smell ID datasets and refine its AI-driven solutions.
Read more →AIMDAinos Reports Full Year 2025 Financial Results and Highlights Commercial Momentum Entering 2026
Ainos, Inc. reported a substantial 499% revenue growth for 2025, driven by its AI Nose platform. The company has successfully transitioned its focus from healthcare to industrial applications, with deployments already beginning in semiconductor environments. Gross margins improved significantly to 82.9%, reflecting operational discipline. Ainos anticipates further growth in 2026, supported by early-stage implementations and effective partnerships. However, the company faces ongoing risks related to profitability and market competition.
Read more →AIMD▼ -9.8%on this news· ran to -23% by day 1
Ainos Reports Third Quarter 2025 Financial Results olfactory commercialization accelerates toward 2026 scale-up, as industrial partnerships expand to six and the IP moat strengthens.
Ainos, Inc. reported its financial results for Q3 2025, highlighting significant progress in its olfactory commercialization efforts as it gears up for a major scale-up in 2026. The company has successfully added six strategic partnerships in the semiconductor and industrial edge AI sectors, facilitating the deployment of its AI Nose technology. Additionally, Ainos launched the world's first patented AI Nose device, enhancing its competitive edge in the growing electronic-nose market. Its disciplined financial management has led to a notable decline in operational expenses, supporting its commercial strategies and expansion plans.
Read more →AIMDAinos Reports Second Quarter 2025 Financial Results 2025 Kicks Off AI Nose's Growing Commercial Momentum with First Senior Care Revenue and New Strategic Partnerships
Ainos, Inc. has reported strong financial results for the second quarter of 2025, highlighting the successful transition of its AI Nose platform from research and development to revenue-generating activities. The company secured significant collaboration agreements, including a $2.1 million subscription order with ASE Technology for semiconductor applications. Ainos is also gaining momentum in the senior care sector, having achieved its first commercial revenues in this space. The company's strategic roadmap outlines ambitious plans for scaling operations and expanding its market reach in various industries by the end of 2025.
Read more →AIMD▲ +39.9%on this news
Ainos Secures $2.1 Million Order With ASE for First Deployment of AI Nose in Semiconductor Manufacturing Setting Revenue-Generating Milestone for AI Nose Smell Language Model in High-Value Industrial Applications
Ainos, Inc. has announced a significant milestone by securing a $2.1 million subscription order with ASE Technology Holding Co. for the deployment of its AI Nose platform in semiconductor manufacturing. This order includes the deployment of 1,400 AI Nose units across three major manufacturing sites in Taiwan and represents Ainos' first revenue-generating success in high-value industrial applications. The company is also planning further deployments in Japan, aiming to strengthen its presence in the Asian market and enhance smart manufacturing with its innovative scent digitization technology.
Read more →AIMDRegains Nasdaq Compliance, Sets 90-Day Roadmap to Scale AI Nose Platform in 2026 Momentum Accelerates with Partnerships to Drive AI-Powered Scent Intelligence for IndustrialAI and HealthcareAI
Ainos Inc. (NASDAQ:AIMD) has announced its return to compliance with Nasdaq’s minimum bid price requirement, enabling its continued presence on the exchange. The company is focusing on scaling its AI Nose platform with a 90-day roadmap, aiming for large-scale commercialization by 2026. Partnerships with major firms like ASE Technology Holding are central to this growth, alongside achieving significant revenue increases. However, challenges such as future profitability and competition in the market are acknowledged as risks to the company's ambitious plans.
Read more →AIMDAinos and Kenmec Launch Strategic Partnership to Deploy AI-Powered Scent Intelligence in Smart Factories Across Asia Nose and SLM SmellTech platform enter scale-up phase targeting robotics, automation, and environmental sensing markets
Ainos, Inc. has partnered with Kenmec Mechanical Engineering to deploy AI-powered scent intelligence in smart factories across Asia. This strategic partnership aims to integrate Ainos' AI Nose and Smell Language Model into Kenmec's automation solutions, enhancing real-time environmental diagnostics in various sectors including logistics and healthcare. Both companies plan to showcase their technology jointly at Automation Taipei 2025. The collaboration is expected to accelerate growth in the emerging digital scent technology market.
Read more →AIMDAinos Reports First Quarter 2025 Financial Results
Ainos, Inc. reported a remarkable 412% increase in revenues for Q1 2025, primarily due to its AI Nose products, marking a turnaround to gross profit from a previous loss. The company is leveraging strategic partnerships in robotics and semiconductors to broaden the application of its technology, enhancing its market position. Additionally, Ainos received crucial approvals for two clinical trials in Taiwan, focusing on developing innovative therapeutics targeting specific health issues. This strong financial performance reflects early traction and a strategic shift aimed at long-term growth.
Read more →AIMDAinos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories
Ainos, Inc. has announced a partnership with Advanced Semiconductor Engineering (ASE) to implement AI-powered scent digitization in semiconductor manufacturing. This collaboration aims to enhance operational efficiency, environmental safety, and compliance with ESG regulations using patented AI Nose technology. The AI Nose, originally designed for healthcare applications, will now be utilized for monitoring airborne chemicals and optimizing manufacturing processes. The partnership represents a significant expansion of Ainos' product offerings and positions both companies at the forefront of innovation in smart manufacturing.
Read more →AIMDAinos Reports Full Year 2024 Financial Results revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled
Ainos, Inc. announced its financial results for 2024, highlighting a strategic transition from COVID-19 products to advancements in AI Nose technology and the VELDONA drug development pipeline. The AI Nose program, particularly the Ainos Flora device, has shown promising accuracy and aims for commercialization soon. Despite reporting a decrease in revenues and a negative gross profit, Ainos is focused on expanding its product offerings and strategic partnerships to drive future growth. The company also made progress in its drug development for Sjögren's syndrome and animal health initiatives.
Read more →AIMDAinos and ugo to Develop the World's First Robot with a Sense of Smell Major Breakthrough in Ainos' Mission to Digitize Scent
Ainos, Inc. and ugo, Inc. have announced a strategic partnership aimed at developing the world's first robotic systems equipped with olfactory perception through Ainos' AI Nose technology. This collaboration will enhance the capabilities of ugo's robots, allowing them to perform crucial tasks in industrial safety, public health, and security by detecting volatile organic compounds. The deployment of this technology is positioned to address labor shortages across various sectors by improving operational efficiency and workplace safety. The project represents a significant advancement in the integration of artificial intelligence with traditional robotics.
Read more →AIMD▼ -8.3%on this news
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug San Diego, California-(Newsfile Corp.
Ainos, Inc. has announced a strategic partnership with Taiwan Tanabe Seiyaku to advance the manufacturing and market promotion of its drug VELDONA for Sjögren's syndrome. The collaboration aims to address the significant demand for effective treatments in this area. VELDONA is a low-dose oral interferon-alpha that has shown promising results in clinical trials, indicating potential to improve patient symptoms and quality of life. The partnership is expected to facilitate a quicker market introduction of the drug, meeting a pressing healthcare need.
Read more →AIMDAinos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
Ainos, Inc. has announced a breakthrough with its AI Nose technology, achieving 79% accuracy in identifying volatile organic compounds in semiconductor manufacturing. This advancement allows for real-time detection of harmful gas leaks and enhances worker safety in smart factories. The AI Nose aims to be integrated into robotic systems, allowing for better monitoring and response to hazardous conditions. This innovation is expected to significantly improve safety and efficiency in industrial operations.
Read more →AIMD▼ -17.1%on this news
Ainos Reports Second Quarter 2024 Financial Results Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developments Robust financial runway for over 12 months f
Ainos, Inc. has reported its second quarter 2024 financial results, highlighting progress in its clinical study for the treatment of feline chronic gingivostomatitis (FCGS). The company has successfully enrolled its first subject and anticipates completing the trial by early 2025. Despite achieving a robust financial runway for more than 12 months following recent financing, Ainos experienced a decline in revenues due to the cessation of COVID-19 product sales and rising operational costs. Their strategy remains centered on the commercialization of low-dose interferon therapeutics and expanding into the animal health market.
Read more →AIMD▲ +7.3%on this news
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the wa
Ainos, Inc. has announced significant progress in clinical trials for its Ainos Flora device, which utilizes AI technology for point-of-care testing of infections. The trials have reported 75 meaningful case results, demonstrating the device's potential in non-invasive testing. The company plans to leverage NVIDIA CUDA for improvements in their next-generation device, expected to begin trials by Q4. This innovation targets decentralized healthcare solutions, particularly in home testing for STIs and vaginal health.
Read more →AIMDAinos Reports First Quarter 2024 Financial Results Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024 US$9M growth capital secured in May strengthens financial position for executing gr
Ainos, Inc. reported its financial results for Q1 2024, highlighting a strategic pivot away from COVID-19 rapid tests, which has impacted revenue. The company secured US$9 million in growth capital to bolster its financial position, facilitating the advancement of its AI-powered point-of-care testing and drug candidates for HIV. Despite a significant drop in first-quarter revenues compared to the previous year, Ainos continues to diversify its business strategy to enhance long-term sustainability. Operating expenses have increased due to rising costs in clinical trials and staffing.
Read more →AIMD▲ +83%on this news
Ainos Reports Full Year 2023 Financial Results Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of
Ainos, a diversified healthcare company, reported its financial results for 2023, highlighting a strategic pivot toward VELDONA and AI-powered point-of-care testing. The company's revenues fell significantly due to decreased demand for COVID-19 test kits, leading to a negative gross profit. Despite these challenges, Ainos has made promising advances, including moving VELDONA drug candidates to Phase III trials and achieving positive outcomes in clinical studies for its treatment targeting oral warts in HIV-positive patients. The firm aims to diversify its revenue streams and enhance its product offerings in 2024.
Read more →AIMDAinos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms Updated Chemistry, Manufacturing, a
Ainos, Inc. has submitted a clinical hold complete response to the U.S. FDA regarding its VELDONA formulation aimed at treating mild COVID-19 symptoms. This response addresses previously identified deficiencies, paving the way for a Phase II trial expected in Taiwan later in 2024. The company's progress includes the manufacturing of a compliant GMP Clinical Batch, and optimism surrounds VELDONA's potential effectiveness against mild COVID-19. Ainos plans to submit additional IND applications for different health conditions in the near future.
Read more →AIMDAinos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
Ainos, Inc. announced that Jack Lu, the Director of Corporate Development, will present at the Small-Cap Growth Virtual Investor Conference on February 7, 2024. The presentation will allow real-time interaction with investors, along with opportunities for one-on-one meetings. Ainos is a healthcare company focused on innovative testing and therapeutics, expanding its portfolio including low-dose interferon and COVID-19 point-of-care tests. Archived webcasts will be available for those unable to attend the live event.
Read more →AIMDAinos , Inc. Announces Stock Consolidation
Ainos, Inc. has announced a reverse stock split, consolidating five shares into one, effective December 14, 2023. This action aims to manage the company's share structure and may improve its market position. The number of outstanding shares will reduce to approximately 4.68 million, while the company's ticker symbol will remain the same. Ainos focuses on developing point-of-care testing and therapeutics but faces challenges due to financial constraints and market dependence on specific products.
Read more →About Ainos, Inc.
Headquarters3050 POST OAK BLVD,, HOUSTON, TX, 77056
Founded1984
BIOPHARMAWATCH ELITE PLUS
Trade the next AIMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime